Literature DB >> 22511779

p27kip1 protein levels reflect a nexus of oncogenic signaling during cell transformation.

Jeffrey P Miller1, Nancy Yeh, Christoph P Hofstetter, Doruk Keskin, Andrew S Goldstein, Andrew Koff.   

Abstract

SV40 small t-antigen (ST) collaborates with SV40 large T-antigen (LT) and activated rasv12 to promote transformation in a variety of immortalized human cells. A number of oncogenes or the disruption of the general serine-threonine phosphatase protein phosphatase 2A (PP2A) can replace ST in this paradigm. However, the relationship between these oncogenes and PP2A activity is not clear. To address this, we queried the connectivity of these molecules in silico. We found that p27 was connected to each of those oncogenes that could substitute for ST. We further determined that p27 loss can substitute for the expression of ST during transformation of both rodent and human cells. Conversely, knock-in cells expressing the degradation-resistant S10A and T187A mutants of p27 were resistant to the transforming activities of ST. This suggests that p27 is an important target of the tumor-suppressive effects of PP2A and likely an important target of the multitude of cellular oncoproteins that emulate the transforming function of ST.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22511779      PMCID: PMC3370163          DOI: 10.1074/jbc.M112.361972

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status.

Authors:  Anxo Vidal; S Sean Millard; Jeffrey P Miller; Andrew Koff
Journal:  J Biol Chem       Date:  2002-03-01       Impact factor: 5.157

2.  Enumeration of the simian virus 40 early region elements necessary for human cell transformation.

Authors:  William C Hahn; Scott K Dessain; Mary W Brooks; Jessie E King; Brian Elenbaas; David M Sabatini; James A DeCaprio; Robert A Weinberg
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  Critical role for SV40 small-t antigen in human cell transformation.

Authors:  J Yu; A Boyapati; K Rundell
Journal:  Virology       Date:  2001-11-25       Impact factor: 3.616

4.  Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.

Authors:  T Soucek; M Rosner; A Miloloza; M Kubista; J P Cheadle; J R Sampson; M Hengstschläger
Journal:  Oncogene       Date:  2001-08-09       Impact factor: 9.867

5.  Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression.

Authors:  R C O'Hagan; M Ohh; G David; I M de Alboran; F W Alt; W G Kaelin; R A DePinho
Journal:  Genes Dev       Date:  2000-09-01       Impact factor: 11.361

Review 6.  Modelling the molecular circuitry of cancer.

Authors:  William C Hahn; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

7.  Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization.

Authors:  Naoya Fujita; Saori Sato; Kazuhiro Katayama; Takashi Tsuruo
Journal:  J Biol Chem       Date:  2002-05-31       Impact factor: 5.157

8.  Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.

Authors:  Ulrich B Keller; Jennifer B Old; Frank C Dorsey; Jonas A Nilsson; Lisa Nilsson; Kirsteen H MacLean; Linda Chung; Chunying Yang; Charles Spruck; Kelli Boyd; Steven I Reed; John L Cleveland
Journal:  EMBO J       Date:  2007-04-26       Impact factor: 11.598

9.  53BP1 contributes to a robust genomic stability in human fibroblasts.

Authors:  Lauren S Fink; Michaela Roell; Emanuela Caiazza; Chad Lerner; Thomas Stamato; Silvana Hrelia; Antonello Lorenzini; Christian Sell
Journal:  Aging (Albany NY)       Date:  2011-09       Impact factor: 5.682

10.  Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas.

Authors:  W L See; J P Miller; M Squatrito; E Holland; M D Resh; A Koff
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

View more
  7 in total

1.  Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Authors:  Kamonwan Fish; Jia Chen; Richard Longnecker
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

2.  MicroRNA-mediated transformation by the Kaposi's sarcoma-associated herpesvirus Kaposin locus.

Authors:  Eleonora Forte; Archana N Raja; Priscilla Shamulailatpam; Mark Manzano; Matthew J Schipma; John L Casey; Eva Gottwein
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

Review 3.  The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.

Authors:  Erik S Knudsen; Agnieszka K Witkiewicz
Journal:  Trends Cancer       Date:  2017-01

4.  The B55α regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes.

Authors:  Victoria Kolupaeva; Lea Daempfling; Claudio Basilico
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

5.  Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.

Authors:  C Lambrecht; L Libbrecht; X Sagaert; P Pauwels; Y Hoorne; J Crowther; J V Louis; W Sents; A Sablina; V Janssens
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

6.  The B56γ3 regulatory subunit-containing protein phosphatase 2A outcompetes Akt to regulate p27KIP1 subcellular localization by selectively dephosphorylating phospho-Thr157 of p27KIP1.

Authors:  Tai-Yu Lai; Chia-Jui Yen; Hung-Wen Tsai; Yu-San Yang; Wei-Fu Hong; Chi-Wu Chiang
Journal:  Oncotarget       Date:  2016-01-26

Review 7.  The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.

Authors:  Peter P Ruvolo
Journal:  BBA Clin       Date:  2016-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.